扶正化瘀片与恩替卡韦联合治疗乙肝肝硬化的效果及对HBV-DNA载量的影响  

Effect of Fuzheng Huayu tablets combined with entecavir in the treatment of hepatitis cirrhosis and its influence on HBV-DNA load

作　　者：赵丹 ZHAO Dan(Department of Pharmacy,Zhenjiang Third People's Hospital,Zhenjiang Jiangsu 212000,China)

机构地区：[1]镇江市第三人民医院药剂科,江苏镇江212000

出　　处：《天津药学》2025年第1期41-43,47,共4页Tianjin Pharmacy

摘　　要：目的探讨扶正化瘀片与恩替卡韦联合治疗乙肝肝硬化的临床效果。方法选取2022年2月至2024年2月镇江市第三人民医院收治的乙肝肝硬化患者88例,按随机数字表法分为2组,各44例。对照组采用恩替卡韦治疗,观察组采用恩替卡韦和扶正化瘀片治疗,两组均持续治疗6个月。比较两组临床疗效、肝功能指标、肝纤维化指标、乙型肝炎病毒(HBV)-DNA载量及不良反应。结果观察组总有效率高于对照组,有统计学差异(P<0.05);观察组治疗后丙氨酸转氨酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)水平分别为(24.42±2.85)U/L、(33.56±3.57)U/L、(21.14±2.75)μmol/L,低于对照组的(28.95±2.97)U/L、(40.42±4.13)U/L、(26.35±2.89)μmol/L,有统计学差异(P<0.05);观察组治疗后层粘连蛋白(LN)、透明质酸(HA)和Ⅳ型胶原(Ⅳ-C)、HBV-DNA载量分别为(62.82±6.19)ng/mL、(101.14±9.63)ng/mL、(71.15±6.72)ng/mL、(1.05±0.22)log拷贝/mL,低于对照组的(70.39±6.27)ng/mL、(112.43±9.72)ng/mL、(79.53±7.13)ng/mL、(1.57±0.26)log拷贝/mL,有统计学差异(P<0.05);两组不良反应发生率相比,无统计学差异(P>0.05)。结论联用扶正化瘀片联合恩替卡韦可提高乙肝肝硬化患者疗效,降低HBV-DNA载量,抑制肝损伤进展,安全可靠。Objective To explore the clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of hepatitis B cirrhosis.Methods From February 2022 to February 2024,88 patients with hepatitis B cirrhosis who were admitted to the Zhenjiang Third People's Hospital were selected and divided into two groups according to the random number table,with 44 cases in each group.The control group was treated with entecavir,while the observation group was treated with entecavir and Fuzheng Huayu tablets.Both groups received continuous treatment for 6 months.The clinical efficacy,liver function indexes,liver fibrosis indexes,hepatitis B virus(HBV)-DNA load and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,with statistical difference(P<0.05).The levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),and total bilirubin(TBIL)in the observation group after treatment were(24.42±2.85)U/L,(33.56±3.57)U/L,and(21.14±2.75)μmol/L,respectively,which were lower than those in the control group[(28.95±2.97)U/L,(40.42±4.13)U/L,and(26.35±2.89)μmol/L],with statistical differences(P<0.05).The levels of laminin(LN),hyaluronic acid(HA),type IV collagen(IV-C),and HBV-DNA in the observation group after treatment were(62.82±6.19)ng/mL,(101.14±9.63)ng/mL,(71.15±6.72)ng/mL,and(1.05±0.22)log copy/mL,respectively,lower than those in the control group[(70.39±6.27)ng/mL,(112.43±9.72)ng/mL,(79.53±7.13)ng/mL,and(1.57±0.26)log copy/mL],with statistical differences(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion Fuzheng Huayu tablets combined with entecavir can improve the curative effect of patients with hepatitis B cirrhosis,reduce the HBV-DNA load,inhibit the progress of liver injury,and is safe and reliable.

关 键 词：乙肝肝硬化 扶正化瘀片 恩替卡韦 HBV-DNA载量 不良反应 

分 类 号：R512.62[医药卫生—内科学]